Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for High Risk COVID-19
NCT04355897Phase 1Completed
- Sponsor
- The Christ Hospital
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by The Christ Hospital. Primary endpoint: Reduce mortality at Day 28. Started Apr 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04355897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355897.